|drug2705||Standard of Care Triple IS Wiki||1.00|
|drug2698||Standard of Care Wiki||0.18|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
The primary objective of this study is to assess whether the use of lenzilumab in addition to current standard of care can alleviate the immune-mediated cytokine release syndrome (CRS) and reduce the time to recovery in hospitalized subjects with severe or critical COVID-19 pneumonia.
Description: Time to recovery is defined as the first day on which a subject satisfies one of the following 3 categories from the 8-point ordinal scale (Hospitalized, not requiring supplemental oxygen-no longer requires ongoing medical care; Not hospitalized, limitation on activities and/or requiring home oxygen; Not hospitalized, no limitations on activities).Measure: Time to Recovery Time: Up to 28 days
Description: Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0Measure: Percentage of Participants Experiencing Adverse Events Time: Up to 60 days
Description: Using the NCI CTCAE version 5.0Measure: Percentage of Participants Experiencing Serious Adverse Events Time: Up to 60 days
Description: NEWS2 consists of: Physiological Parameters: respiration rate (per minute), SpO2 Scale 1 (%), SpO2 Scale 2 (%), use of air or oxygen, systolic blood pressure (mmHg), pulse (per minute), consciousness and temperature (°C)Measure: Time to Clinical Improvement, Defined as NEWS2 < 2 Maintained for 24 Hours Time: Up to Day 28